Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma

Kaori Ito\textsuperscript{a, b}, Masataka Okamoto\textsuperscript{b}, Yoko Inaguma\textsuperscript{b}, Akinao Okamoto\textsuperscript{b}, Maiko Ando\textsuperscript{a, b}, Yosuke Ando\textsuperscript{a}, Masahiro Tsuge\textsuperscript{a}, Ayana Tomono\textsuperscript{a}, Yukiko Kakumae\textsuperscript{a}, Takahiro Hayashi\textsuperscript{a}, Shigeki Yamada\textsuperscript{a}, Nobuhiko Emi\textsuperscript{b}

\textsuperscript{a}Department of Pharmacy, Fujita Health University Hospital, and \textsuperscript{b}Department of Hematology, Fujita Health University School of Medicine, Aichi, Japan

Abstract

Objective: To assess the immunosuppressive effect of R-CHOP in patients with B-cell lymphoma at 2 years. Methods: Parameters of humoral and cell-mediated immunity were assessed in 89 patients with diffuse large B-cell lymphoma or follicular lymphoma before and after 6–8 cycles of R-CHOP-14 or R-CHOP-21 regimen. Results: Data on pre- and posttreatment serum IgG (sIgG) levels were available for all 89 patients, while the corresponding data on serum CD20\textsuperscript{+}, CD3\textsuperscript{+}, CD4\textsuperscript{+}, and CD8\textsuperscript{+} lymphocyte counts were available in only 43. Median sIgG levels significantly decreased from 1,221 mg/dl (baseline) to 733 mg/dl (after chemotherapy) (p < 0.001). Although CD20\textsuperscript{+} and CD4\textsuperscript{+} cell counts decreased (p < 0.001), no significant effect of chemotherapy on CD3\textsuperscript{+} and CD8\textsuperscript{+} cell counts was observed. CD20\textsuperscript{+} cell counts were restored to baseline levels at the 12-month follow-up. sIgG levels and CD4\textsuperscript{+} cell counts were not completely restored at 24 months, indicating a sustained immunosuppressive effect of R-CHOP in these patients. The incidence of infections over the 2-year period was 16.3–23.6%. Conclusion: The immunosuppressive effect of R-CHOP in newly diagnosed cases of B-cell lymphoma tends to persist for >2 years, although sIgG levels were restored more quickly than CD4\textsuperscript{+} cell counts.

Introduction

R-CHOP therapy is the standard first-line treatment for B-cell lymphoma [1–3]. In Japan, R-CHOP therapy is confined to the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). However, the standard first-line treatment for follicular lymphoma (FL) has not been determined, although R-CHOP or R-COP therapy is often conventionally used. CHOP therapy comprises cytotoxic drugs, namely cyclophosphamide, doxorubicin, vincristine, and prednisolone (steroid); R-CHOP therapy includes rituximab with the abovementioned drugs. Rituximab is a chimeric monoclonal antibody against CD20 and exerts antineoplastic effects by producing antibody-dependent cellular cytotoxicity, particularly by inducing complement-dependent cytotoxicity [4, 5]. In a previous study, R-CHOP therapy significantly prolonged time to treatment failure as well as overall survival among patients with symptomatic, advanced-stage FL.
compared with CHOP therapy [6]. In a subsequent study, R-CHOP therapy significantly increased the rates of complete responses, decreased the rates of treatment failure and relapse, and improved event-free and overall survival of elderly patients with newly diagnosed DLBCL compared with CHOP therapy [7]. Moreover, R-CHOP therapy was reportedly effective in patients with non-Hodgkin’s lymphoma, and it is recognized as the standard treatment for B-cell lymphoma [8, 9].

In previous studies [10, 11], B cells were reconstituted after rituximab monotherapy, whereas B cell count was rapidly depleted and slowly recovered over 3–6 months and required approximately 1 year for complete restoration. In contrast, rituximab monotherapy did not have a significant effect on CD3+, CD4+, and CD8+ T-cell counts. In agreement, an immunological study showed that circulating B cells disappeared early after rituximab monotherapy, whereas T-helper cells (CD3+/CD4+), T-suppressor cells (CD3+/CD8+), and NK cell count remained stable [12–15]. Although the influence of rituximab monotherapy on immune system restoration has been examined in several studies, only few studies have described the influence of R-CHOP therapy on immune system restoration.

Nonetheless, Kurokawa et al. [16] reported the recovery of B-cells over 1 year and CD4+ T-cells and immunoglobulin over 2 years after the chemotherapy in patients with B-cell lymphoma who received R-CHOP-like regimen (cyclophosphamide, 750 mg/m² on day 1; pirarubicin, 50 mg/m² on day 1; vincristine, 1.4–2 mg on day 1; prednisolone, 100 mg/body on days 1–5; and rituximab 375 mg/m² administered before each of the cycles). Moreover, no previous studies reported the immune function restoration for 2 years after R-CHOP therapy. Thus, we conducted a retrospective study where the influence of R-CHOP therapy was investigated after 2 years on immune system restoration and infection rate in patients with B-cell lymphoma.

Subjects and Methods

Patients who received 6–8 cycles of R-CHOP or R-COP regimens as initial treatments for DLBCL or FL were recruited between April 2004 and April 2011 from the Fujita Health University Hospital. Patients received 375 mg/m² rituximab on day 1 of CHOP therapy comprising 750 mg/m² cyclophosphamide, 50 mg/m² doxorubicin, and 1.4 mg/m² vincristine on day 1, and 50 mg/m² or 100 mg prednisolone on days 1–5 of 14- or 21-day cycles. Patients who were treated with rituximab monotherapy were not included, and doses of cyclophosphamide, doxorubicin, vincristine, and prednisolone were reduced by 20% in patients aged >70 years.
Immune Function before and after Chemotherapy

Humoral (sIgG level) and cellular immune parameters (CD20+, CD3+, CD4+, and CD8+ cell counts as well as CD4+/8+ ratios) were determined before and after chemotherapy and at 3, 6, 9, 12, 15, 18, 21, and 24 months (±1 month) after the completion of chemotherapy. In these analyses (fig. 1), median sIgG levels significantly decreased (40%) from 1,214 mg/dl before to 733 mg/dl after chemotherapy (p < 0.001). However, sIgG levels were significantly recovered after 3 months (fig. 1).

The median baseline CD20+ cell count was 144/μl and decreased rapidly to 0/μl after chemotherapy completion (p < 0.001; fig. 1). Subsequently, CD20+ cell counts remained low for 6 months and then recovered to approximately 85.7% of baseline levels at 1 year and to 100% at 2 years after chemotherapy. In contrast, CD3+ lymphocyte counts did not decrease following chemotherapy (p = 0.126, fig. 2), although CD4+ cell counts decreased from 590/μl at baseline to 239/μl after chemotherapy (p < 0.001), representing a 40.5% decrease in median CD4+ cell counts. CD8+ cell counts after chemotherapy (fig. 2) did not differ from those at baseline (p = 0.207). The median baseline CD4+/8+ ratio was 1.78 and was significantly decreased to 0.80 (p < 0.001) after chemotherapy and remained low for the subsequent 2 years.

Restoration of sIgG Levels and CD4+ Cell Counts after Chemotherapy

Both sIgG levels and CD4+ cell counts were significantly decreased after chemotherapy and did not return to baseline values at 6, 12, 18, and 24 months (±2 months) after chemotherapy. However, baseline sIgG levels (table 2) did not differ between the four time points, and the percentages of baseline sIgG levels slightly increased over the study period. CD4+ cell counts at follow-up were expressed as percentages of baseline counts in table 3 and did not differ between follow-up time points. The restoration of sIgG levels and CD4+ cell counts did not differ between the patient groups aged >70 years and ≤70 years at 6 and 24 months (data not shown).

Restoration Rates

Percentages of patients with 70% or 90% restoration of baseline sIgG levels and CD4+ cell counts were calculated
The percentages of patients with 70% and 90% CD4+ cell count restoration rates did not differ between the 6- and 24-month time points, whereas the percentages of patients with restored sIgG levels were significantly greater at 24 months than at 6 months. Specifically, 70% recovery rates of sIgG levels from baseline increased over time, and at 24 months, 85.2 and 51.9% of the present patients achieved 70 and 90% restoration of sIgG, respectively. No patients developed hypogammaglobulinemia at 24 months.

To explore the risk factors which cannot achieve 70% restoration of baseline sIgG levels, univariate analysis was performed to identify risk factors, and variables with a significance level of <20% were included in the multivariate logistic regression model. Multivariate logistic regression analysis did not demonstrate an association with the aforementioned parameters (data not shown). Additionally, 90% restoration of baseline sIgG levels and 70 or 90% restoration of baseline CD4+ cell counts did not demonstrate an association either (data not shown).

**Fig. 1.** Kinetics of sIgG level and CD20+ cell count in peripheral blood. The data were obtained before and after chemotherapy, and at 3, 6, 9, 12, 15, 18, 21, and 24 months (±1 month) after chemotherapy completion. Data are expressed as medians.

**Fig. 2.** Kinetics of each lymphocyte subset (CD3+, CD4+, and CD8+) cell count in peripheral blood. The data were obtained before and after chemotherapy, and at 3, 6, 9, 12, 15, 18, 21, and 24 months (±1 month) after chemotherapy completion. Data are expressed as medians.
**Table 2. sIgG levels**

<table>
<thead>
<tr>
<th>Period after chemotherapy</th>
<th>Patients</th>
<th>sIgG at baseline/after chemotherapy, mg/dl</th>
<th>% of baseline</th>
<th>p value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>55</td>
<td>1,183 (1,031–1,397)/913 (748–1,048)</td>
<td>77.0 (62.8–91.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>12 months</td>
<td>58</td>
<td>1,226 (1,021–1,407)/990 (798–1,226)</td>
<td>82.7 (68.9–95.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>18 months</td>
<td>38</td>
<td>1,185 (1,031–1,420)/1,026 (824–1,259)</td>
<td>85.6 (73.4–95.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>24 months</td>
<td>24</td>
<td>1,205 (1,094–1,341)/1,049 (907–1,400)</td>
<td>94.7 (74.3–104.2)</td>
<td>0.027</td>
</tr>
<tr>
<td>p value&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.993/0.081</td>
<td>0.085</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The data were obtained before chemotherapy and at 6, 12, 18, and 24 months (±2 months) after chemotherapy completion. All data are expressed as median (first quartile–third quartile). % of baseline = Baseline divided by After chemotherapy × 100. <sup>a</sup> Wilcoxon signed-rank test. <sup>b</sup> Kruskal-Wallis test.

**Table 3. CD4+ cell counts**

<table>
<thead>
<tr>
<th>Period after chemotherapy</th>
<th>Patients</th>
<th>CD4+ cell counts at baseline/after chemotherapy, /μl</th>
<th>% of baseline</th>
<th>p value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>26</td>
<td>603 (329–777)/333 (255–495)</td>
<td>60.1 (49.5–83.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>12 months</td>
<td>29</td>
<td>544 (281–777)/410 (256–595)</td>
<td>66.2 (47.8–129.9)</td>
<td>0.037</td>
</tr>
<tr>
<td>18 months</td>
<td>25</td>
<td>544 (230–777)/465 (193–535)</td>
<td>73.0 (51.2–123.2)</td>
<td>0.045</td>
</tr>
<tr>
<td>24 months</td>
<td>22</td>
<td>669 (298–923)/403 (284–585)</td>
<td>72.9 (52.8–115.3)</td>
<td>0.038</td>
</tr>
<tr>
<td>p value&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.811/0.741</td>
<td>0.575</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The data were obtained before chemotherapy and at 6, 12, 18, and 24 months (±2 months) after chemotherapy completion. All data were expressed in a form of median (first quartile–third quartile). % of baseline = Baseline divided by After chemotherapy × 100. <sup>a</sup> Wilcoxon signed-rank test. <sup>b</sup> Kruskal-Wallis test.

**Table 4. Percentage of patients with 70 or 90% restoration of baseline sIgG level or CD4+ cell count**

<table>
<thead>
<tr>
<th>sIgG level</th>
<th>6 M (n = 55)</th>
<th>24 M (n = 24)</th>
<th>p value</th>
<th>CD4+ cell count</th>
<th>6 M (n = 26)</th>
<th>24 M (n = 22)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>70% restoration</td>
<td>60.0%</td>
<td>85.2%</td>
<td>0.021</td>
<td>42.3%</td>
<td>63.6%</td>
<td>0.141</td>
<td></td>
</tr>
<tr>
<td>90% restoration</td>
<td>27.3%</td>
<td>51.9%</td>
<td>0.029</td>
<td>23.1%</td>
<td>45.5%</td>
<td>0.101</td>
<td></td>
</tr>
</tbody>
</table>

The data were obtained at 6 and 24 months (±2 months) after chemotherapy completion. Data are expressed as the percentage of population.
Influence of R-CHOP Therapy on Immune System Restoration

Infectious Complications

The number of patients who suffered infections between starting chemotherapy and the last follow-up was counted (Table 5). The rate of infection during chemotherapy was 30.3–32.6%, and the rate of infection during the observation period was 16.3–23.6%.

The rate of infection in the subgroup with ≥70% of baseline sIgG levels was 26.1% during chemotherapy and 47.8% during the observation period. The corresponding rate in the subgroup with <70% of baseline sIgG levels was 25.0 and 75.0%, respectively. In both groups, no significant differences were observed between the rates of infection during chemotherapy and that during the observation period (p = 0.56, 0.64, respectively). Similarly, no significant differences were observed when we compared the patients with ≥90% of baseline sIgG levels and those with <90% of baseline sIgG levels (data not shown).

The rate of infection in the subgroup with ≥70% of baseline CD4+ cell counts was 8.3% during chemotherapy and 25.0% during observation. The corresponding rates of infection in the group with <70% of baseline CD4+ cell counts were 30.0 and 50.0%, respectively. Infection rates in the group with <70% of baseline CD4+ cell counts were higher (both during chemotherapy and observation period) than those in the group with ≥70% of baseline CD4+ cell counts. However, the between-group difference was not statistically significant (p = 0.45, 0.44). Similarly, no significant differences were observed when we compared the patients with ≥90% of baseline CD4+ cell counts and those with <90% of baseline CD4+ cell counts (data not shown).

Discussion

In this study, we evaluated the effects of R-CHOP therapy on humoral and cell-mediated immunity in patients with newly diagnosed B-cell lymphoma of either DLBCL or FL. Our findings revealed marked decreases in sIgG levels and CD4+ counts immediately after treatment and subsequent restoration over 2 years. However, the restoration rates of CD4+ counts (indicative of cell-mediated immunity) were less than those of sIgG levels (indicative of humoral immunity).

Previously, Kurokawa et al. [16] reported the effects of CHOP-based chemotherapy containing rituximab on immune function in 66 patients with newly diagnosed malignant lymphoma. However, 21 patients (31.8%) were aged at least 70 years, and some patients received THP-CHOP therapy, in which doxorubicin was replaced with tetrahydropyranyl adriamycin. Hence, their study results were not solely reflective of R-CHOP therapy and may, thus, lack consistency with the results of the present study; in addition, the immunological effects of tetrahydropyranyl adriamycin remain uncharacterized. In contrast, to ensure the homogeneity of treatments in the present study, elderly patients aged ≥70 years received 20% reduced dosages of anticancer drugs. In addition, the reduced dosages of anticancer drugs did not influence the restoration of sIgG levels and CD4+ cell counts at 6 and 24 months. The generally lower immunity in older people is a plausible explanation, although further investigation is necessary to arrive at a definitive conclusion. Nonetheless, in agreement with Kurokawa et al. [16], gradual re-

Table 5. Infectious complications between the start of chemotherapy and the last follow-up

<table>
<thead>
<tr>
<th></th>
<th>sIgG (n = 89)</th>
<th>Lymphocyte subsets (n = 43)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>during</td>
<td>during</td>
</tr>
<tr>
<td></td>
<td>chemotherapy</td>
<td>observation</td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pneumocystis pneumonia</td>
<td>0</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Herpes simplex virus</td>
<td>5 (5.6)</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>Herpes zoster virus</td>
<td>2 (2.2)</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>Hepatitis B virus reactivation</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Candida</td>
<td>4 (4.5)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>6 (6.7)</td>
<td>1 (1.1)</td>
</tr>
<tr>
<td>Other infections</td>
<td>10 (11.2)</td>
<td>10 (11.2)</td>
</tr>
<tr>
<td>Total</td>
<td>27 (30.3)</td>
<td>21 (23.6)</td>
</tr>
</tbody>
</table>

Values indicate n (%) of patients affected.
covery of sIgG levels and CD4+ counts were observed over 2 years; the restoration rates of sIgG and CD4+ cells at 6, 12, and 18 months after treatment confirmed time-dependent recovery of these immune functions following R-CHOP therapy.

Moreover, although the 70% recovery rates of sIgG levels from baseline increased at 6 and 24 months, CD4+ counts were not improved. Kurokawa et al. [16] did not directly compare two variables in their study but reported a mean sIgG restoration rate of 93.9% at 2-year follow-up. Although the present data lack sufficient distribution normality for comparisons with previous studies, a sub-analysis revealed considerably greater rates of 70% sIgG restoration than 90% restoration after 2 years. These analyses indicate that humoral and cell-mediated immunity have little probability of being fully recovered to baseline at 2 years following R-CHOP therapy in patients with newly diagnosed malignant lymphoma. On the other hand, the infectious complication rate was unexpectedly low at 16.3–23.6% in the observation period, whereas it was high for chemotherapy at 30.3–32.6%. The reason for this discrepancy was expected to be that a follow-up survey provides insufficient information because the observation period was just over 2 years. However, the infectious complication rate was not at all low. In patients at an increased risk of infectious diseases in particular, sIgG levels and CD4+ counts should be regularly monitored, or prophylactic antibiotics should be used.

This retrospective analysis was limited to a small sample size (89 patients), reflecting a small number of patients who completed all measurements at several time points before and after treatment. Accordingly, the numbers of sIgG measurements differed from the estimates of lymphocyte cell numbers. However, no differences in age were identified between treatment groups, and all the included pharmacokinetic data were collected within ±1 month of designated time points. Nonetheless, percentage changes were calculated from data that were collected within ±2 months of baseline and at 24 months, allowing inclusion of a greater number of patients. Furthermore, baseline characteristics of patients showed much divergence, which may have impacted on the analysis. However, on multivariate analysis, we were able to account for baseline differences to some extent. On subgroup analyses of infection rates, no significant difference was observed in infection rates between patients with ≥70% of baseline sIgG levels (or ≥70% of baseline CD4+ cell counts) and those with <70% of baseline sIgG levels (or <70% of baseline CD4+ cell counts, respectively). Out of 89 cases, complete data on IgG levels and CD4+ cell counts up to 24 months was available only for 24 and 22 cases, respectively. In addition, the relatively short follow-up period did not allow for meaningful estimates of the effect on overall survival and progression-free survival. The effect of R-CHOP therapy on survival requires an additional study with a longer duration of follow-up. Lastly, we did not investigate the effects of R-CHOP therapy on the immune system components other than IgG, B cells, and T cells. We believe that we need to investigate changes in other immune cells, such as NK cells, in future studies.

Several studies report the effects of rituximab monotherapy on immune parameters. In particular, Maloney et al. [10] examined the effect of rituximab monotherapy in 20 patients with relapsed B-cell lymphoma and reported no effects on mean CD3+, CD4+, and CD8+ cell counts or sIgG levels, although sIgG levels were reportedly decreased by ≥20% in 2 patients. Similarly, Anolik et al. [17] investigated the restoration of B cell numbers after rituximab monotherapy for non-Hodgkin lymphoma and reported sustained increases in percentages of transitional B cells and very slow increases in the number of memory B cells, which remained at very low levels even at 1 year after rituximab treatment. In three consecutive sponsor-initiated clinical trials of rituximab monotherapies in Japanese patients with relapsed or refractory B-cell lymphoma, weekly treatments with rituximab for 4 or 8 weeks led to no significant decreases in mean sIgG levels. Ghielmi-ni et al. [14] found that prolonged treatment with rituximab monotherapy for FL induces the persistent depletion of B cells and progressive reduction of serum IgM levels. Hence, the effect of rituximab alone on the restoration of immunity after treatment remains unknown. On the other hand, multiple chemotherapy for initial or relapsed B-cell lymphoma was reportedly complicated by hypogammaglobulinemia, implying a clinical role for rituximab [18–21]. Among the cytotoxic agents of R-CHOP, cyclophosphamide and doxorubicin have well-documented detrimental effects on immunoglobulins and lymphocytes. However, the effects of rituximab in R-CHOP therapy on immune function remain unknown. Moreover, hypogammaglobulinemia has been reported in patients with autoimmune diseases following rituximab monotherapy [22, 23]. Ricardo et al. [24] also compared treatments for chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas, and showed that R-B therapy decreased CD4+ and CD8+ cell counts to a greater extent than R-CHOP therapy. In a recent study involving only a small number of patients with refractory or relapsed FL and mantle cell lymphoma, both CD4+ counts and sIgG levels did not completely recover at 1
year after R-B therapy [25]. Gafter-Gvili and Polliack [26] described that myelosuppression including lymphopenia occurs relatively frequently after R-B therapy and results in secondary hypogammaglobulinemia. In Japan, R-B therapy is not accepted as the standard first-line treatment for B-cell lymphoma. Therefore, direct comparisons between the aforementioned and the present studies were precluded by differing methodological approaches, and more rigorous comparisons with other chemotherapies are warranted. Thus, further studies are required to quantify the immunological effects of rituximab in R-CHOP therapy using direct comparisons with CHOP therapy.

Suppression of humoral and cell-mediated immunity tends to persist for >2 years after R-CHOP therapy in patients with newly diagnosed B-cell lymphoma, although slgG levels were restored more quickly than CD4+ counts.

These findings suggest that in patients at increased risk of infectious disease in particular, slgG levels and CD4+ counts should be regularly monitored for >2 years after R-CHOP therapy, or prophylactic antibiotics should be used.

Acknowledgments

We thank the participating patients for their contribution to this study and the staff of pharmacy, hematology, and nursing, Fujiita Health University Hospital, that cooperated with our study.

Disclosure Statement

The authors have nothing to disclose in association with the publication of this study.

References


6. Hiddemann W, Kneba M, Drevling M, Schmitz N, Lengfelder E, Schulte G, Schulte G, Walewski J, Zinzani PL, Stahel R, Löeffler M, MabThera International Trial: Frontline therapy for B-cell lymphoma. Therefore, direct comparisons between the aforementioned and the present studies were precluded by differing methodological approaches, and more rigorous comparisons with other chemotherapies are warranted. Thus, further studies are required to quantify the immunological effects of rituximab in R-CHOP therapy using direct comparisons with CHOP therapy.


Influence of R-CHOP Therapy on Immune System Restoration

Oncology 2016;91:302–310
DOI: 10.1159/000449251


